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Abstract
Background: Many alterations are involved in mammary oncogenesis, including amplifications of oncogenes and
losses of tumor suppressor genes (TSG). Losses may affect almost all chromosome arms and many TSGs remain to
be identified.
Results: We studied 307 primary breast tumors and 47 breast cancer cell lines by high resolution array
comparative genomic hybridization (aCGH). We identified a region on 18p11.31 lost in about 20% of the tumors
and 40% of the cell lines. The minimal common region of loss (Chr18:6,366,938-6,375,929 bp) targeted the L3MBTL4
gene. This gene was also targeted by breakage in one tumor and in two cell lines. We studied the exon sequence
of L3MBTL4 in 180 primary tumor samples and 47 cell lines and found six missense and one nonsense
heterozygous mutations. Compared with normal breast tissue, L3MBTL4 mRNA expression was downregulated in
73% of the tumors notably in luminal, ERBB2 and normal-like subtypes. Losses of the 18p11 region were associated
with low L3MBTL4 expression level. Integrated analysis combining genome and gene expression profiles of the
same tumors pointed to 14 other potential 18p TSG candidates. Downregulated expression of ZFP161, PPP4R1 and
YES1 was correlated with luminal B molecular subtype. Low ZFP161 gene expression was associated with adverse
clinical outcome.
Conclusion: We have identified L3MBTL4 as a potential TSG of chromosome arm 18p. The gene is targeted by
deletion, breakage and mutations and its mRNA is downregulated in breast tumors. Additional 18p TSG candidates
might explain the aggressive phenotype associated with the loss of 18p in breast tumors.
Background
The development and progression of breast cancer is the
result of the accumulation of genetic alterations such as
amplification of oncogenes and deletions of tumor sup-
pressor genes (TSG) in the epithelial cells of the mam-
mary gland. Frequent deletions have been reported on
chromosome arms 1p, 3p, 7q, 8p 9p, 16q and 17p but
only few reports describe such deletions on chromo-
some arm 18p [1-3].
We profiled a series of 307 primary breast tumors and
47 breast cancer cell lines by using high resolution array
comparative genomic hybridization (aCGH). We identi-
fied a region on 18p11.31 deleted in 25% of the tumors
and 40% of the cell lines. We delineated a minimal com-
m o nr e g i o no fd e l e t i o nt h a tt a r g e t e dt h eL3MBTL4
gene. The L3MBTL4 gene is one of the four human
orthologs of Drosophila lethal (3) malignant brain tumor
(l(3)mbt). L(3)mbt is a bona fide TSG in the fly [4,5].
The L3MBTL4 protein contains three “malignant brain
tumor” (MBT) domains. This domain of about 100
amino acid residues is conserved in protostomians and
d e u t e r o s t o m i a n sa n do f t e ne x i s t sa sr e p e a t s[ 6 ] .T h e
MBT domain binds methylated histone residues. The
human genome contains several MBT-containing pro-
teins, some of which have been linked to gene regula-
tory pathways and polycomb-mediated repression, and
to cancer [7]. L3MBTL1 is a TSG implicated in myeloid
malignancies [8], and L3MBTL3 deregulation is asso-
ciated with neuroblastoma [9].
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cancer we searched for mutations by sequence analysis
of 180 primary tumor samples and 47 cell lines. We
found that, in addition to deletions, L3MBTL4 is tar-
geted by mutations. Finally, we found that L3MBTL4
deletions correlate with low mRNA expression and with
the presence of lymph node metastasis, high Scarf-
Bloom-Richardson (SBR) grade and luminal B molecular
subtype.
Our study is the first to identify a region on chromo-
some arm 18p likely to contain a putative TSG involved
in breast oncogenesis, and to show that this TSG may
be L3MBTL4. We did not exclude the existence of other
potential 18p TSGs, some of which could explain the
aggressive phenotype of breast tumors with 18p loss.
Samples and Methods
Breast tumors
Tumor tissues were collected from 307 patients with
primary adenocarcinoma who underwent initial surgery
at the Institut Paoli-Calmettes (Marseille, France)
between 1992 and 2004. Immediately after macroscopic
examination of the surgery specimen by two patholo-
gists, samples containing more than 60% of tumor cells
were obtained, frozen in liquid nitrogen and stored at
-80°C until nucleic acids extraction. The main histoclini-
cal characteristics of tumors are listed in the Additional
file 1, Table S1. Each patient gave written informed con-
sent and the study was approved by our institutional
review committee.
Cell lines
The 47 breast cell lines used in this study were BT-20,
BT-483, HCC1937, CAMA-1, HCC38, HCC1500 [10],
Hs 578T [11], BT-474, BT-549, HCC202, HCC1395,
HCC1569, HCC1806, HCC1954, HCC2218, HME-1,
MCF7, MDA-MB-134, MDA-MB-157, MDA-MB-175,
MDA-MB-231, MDA-MB-361, MDA-MB-415, MDA-
MB-436, MDA-MB-453, MDA-MB-468, SK-BR-3,
SK-BR-7, T47 D, UACC-812, UACC-893, ZR-75-1, ZR-
75-30 (ATTC, Manassas, VA), BrCa-Mz-01, BrCa-Mz-
02 [12], SUM44, SUM52, SUM102, SUM149, SUM159,
SUM185, SUM190, SUM206, SUM225, SUM229 [13],
S68 (V. Catros, Rennes, France), and CAL51 [14]. All
cell lines were grown as recommended by their
suppliers.
DNA and RNA extraction
DNA and RNA were extracted from frozen samples by
using guanidium isothiocynanate and cesium chloride
gradient, as previously described [15]. DNA quality and
RNA integrity were respectively controled on polyacryla-
mide gel electrophoresis and on Agilent Bioanalyzer
( A g i l e n tT e c h n o l o g i e s ,M a s s y ,F r a n c e ) .D N Aw a sa l s o
extracted from a normal area of paraffin-embedded
T8584, T8847, T9193 and T8525 tissues.
Genome analysis by array-comparative genomic
hybridization (aCGH)
Genome profiles were established on 307 tumors and 47
breast cancer cell lines by aCGH using 244K CGH
Microarrays (Hu-244A, Agilent Technologies, Massy,
France) as previously described [16]. A pool of 13 nor-
mal male DNAs was used as reference. Scanning was
done with Agilent Autofocus Dynamic Scanner
(G2565BA, Agilent Technologies). Data analysis was
done and visualized with CGH Analytics 3.4 software
(Agilent Technologies). Extraction of data (log2 ratio)
was done from CGH analytics, while normalized and fil-
tered log2 ratio were obtained from “Feature extraction”
software (Agilent Technologies). Data generated by
probes mapped to × and Y chromosomes were elimi-
nated. The final dataset contained 225,388 unique
probes covering 22,509 genes and intergenic regions
according to the hg17/NCBI human genome mapping
database (build 35). Data were analyzed using circular
binary segmentation (CBS) [17] as implemented in the
DNA copy R/Bioconductor package [18] with default
parameters to translate intensity measurements in
regions of equal copy number, each region being defined
by at least five consecutive probes. Thus, each probe
was assigned a segment value referred to as its
“smoothed” value.
We used a threshold value of |0.33| (log2 ratio) to
define a copy number aberration (CNA) [16]. Identifica-
tion of copy number variations (CNV) was done using
the regions published by McCarroll et al [19] which are
stored in the Database of Genomic Variants (release v8)
[20]. To determine altered regions, we used the GISTIC
algorithm [21], which computes for each genomic seg-
ment through the whole genome a score based on the
frequency of CNA combined with its amplitude, with
bootstrapping to calculate the significance level (p <
0.001). To establish significant association between CNA
and categorical variables, Fisher’se x a c tt e s tw a su s e d .
Gains and losses were handled separately.
Mutation analysis
Sequence analysis was done on 180 out of the 307
breast tumors and on the 47 breast cell lines after
amplification of genomic DNA. Seventeen primers pairs
were designed to amplify L3MBTL4 DNA by polymerase
chain reaction (PCR) (Additional file 1, Table S2). PCR
amplifications were done in a total volume of 25 μl PCR
mix containing at least 10 ng template DNA, Taq buffer,
500 μmol of each deoxynucleotide triphosphate, 100
μmol of each primer and 1 unit of Hot Star Taq DNA
polymerase (Qiagen, Courtaboeuf, France). PCR
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and 95°C 30 sec, annealing T° 55°C 30 sec, 72°C 45 sec
to to 1 min depending on PCR product length, 72°C 10
min, 35 cycles. PCR products were purified using Milli-
pore plate MSNU030 (Millipore SAS, Molsheim,
France). Aliquots (1 μl) of the purified PCR products
were sequenced using Big Dye terminator v1.1 Cycling
Sequencing Kit (Applied Biosystems, Courtaboeuf,
France) including the forward or reverse primer. The
sequencing products were purified through Multi-
Screen-HV 96-well filter plates (Millipore, Billerica, MA,
USA) preloaded with Sephadex G-50 (Sigma, St Louis,
MO, USA). The reactions were run on the ABI 3130XL
Genetic Analyser (Applied Biosystems, Courtaboeuf,
France). The sequence data files were analyzed using the
phred/phrap/consed software. All mutations were con-
firmed by a second round of PCR and sequencing reac-
tions in both directions.
Quantitative real time reverse-transcribed PCR (qRT-PCR)
L3MBTL4 gene expression level was analyzed by qRT-
PCR on a set of 52 out of the 307 tumors. Two μgo f
total RNA, treated beforehand with RNase-free DNase
(Promega, France), was reverse-transcribed using the
SuperScript II RT and 100 ng of randomhexamers (Invi-
trogen, France). PCR reactions were carried out in a
LightCycler 2.0 instrument (Roche, Germany) in a final
volume of 20 μl according to the supplier’s recommenda-
tions using LightCycler FastStart DNA Master
plus SYBR
Green I Kit (Roche, Germany). L3MBTL4 primers,
L3MBTL4-F (CTTGGAGCAAGCTGAAGAGG) and
L3MBTL4-R (TGGAAAGGACTGATCCTTGG) (Sigma-
Aldrich, Austria), were designed to anneal to exon 4 and
exon 6, respectively. Primers for the control gene, GUSB,
were GUSB-F (GAAAATATGTGGTTGGAGAGCT)
and GUSB-R (CCGAGTGAAGATCCCCTTTTTA)
(Sigma-Aldrich, Austria). The mean threshold cycle (Cp)
was calculated for each gene and ΔCp was defined as
ΔCp = Cp (GUSB) - Cp (L3MBTL4). The ΔCp was deter-
mined on two to six times for each sample and the mean
calculated. The fold ratio of L3MBTL4 transcripts was
calculated using the equation, fold ratio = 2
ΔCp.C o m -
mercial pools of normal breast RNA (Clontech, Palo
Alto, CA) were analyzed and used as control.
Gene expression profiling with DNA microarrays
A total of 229 tumors studied by aCGH, as well as
4 normal breast tissue samples, were profiled with Affy-
metrix U133 Plus 2.0 human oligonucleotide microar-
rays as previously described [22]. Scanning was done
with Affymetrix GeneArray scanner. Data were analyzed
by ‘Robust Multichip Average’ (RMA) with the non-
parametric quantile algorithm as normalization para-
meter in R/Bioconductor and associated packages [18].
All probes were mapped based on their EntrezGeneID.
When multiple probes were mapped to the same gene,
the probe sets with an extension « at », next « s_at »,
and followed by all other extensions were preferentially
kept. When several probe sets with the best extension
were available, the one with the highest median value
was retained.
The five molecular subtypes related to the intrinsic
breast cancer tumor classification were determined
using the single sample predictor (SSP) classifier [23]
associated to ‘Distance Weighted Discrimination’
(DWD) as data set adjustment [24].
Prior statistical analyses L3MBTL4 expression level in
samples was centered using its expression level in the 4
normal breast samples pooled. Over- and under-expres-
sion were defined using a two-fold threshold i.e. |1| in
the log2 transformed data.
Comparative analyses of genome and expression data
To identify other potential 18p TSGs we compared the
degree of CNA-driven RNA downregulation in 229 of
the 307 samples by analyzing the genes common to the
genome and expression platforms (aCGH Agilent Tech-
nologies and Affymetrix) and retained after filtering
based on the expression level. Briefly, a potential TSG
had to show a lower expression value in a sample with
loss than in those without (Student t test) and an under-
expression frequency overrepresented in samples with
the loss (Fisher’s exact test). For both tests significance
level was 5% with a false discovery rate (FDR, [25]) less
than 1%.
Statistical analyses
Correlations between L3MBTL4 CNA groups and histo-
clinical factors were calculated with the Fisher’s exact
test. Student’s t test and one-way ANOVA test were
used to evaluate association of L3MBTL4 gene expres-
sion level within histoclinical factors. Overall specific
survival (OS) and metastasis-free survival (MFS) curves
were estimated using the Kaplan-Meier method and sta-
tistical significance of pairwise comparisons was assessed
using the log-rank test. OS and MFS follow-up times
were measured from the date of diagnosis till death
from breast cancer and till the first occurrence of dis-
tant metastases, respectively. All statistical tests were
two-sided at the 5% level of significance. Statistical ana-
lysis was done using the survival package (version 2.30),
in the R software (version 2.9.1).
Results
Losses and breakages of 18p targets the L3MBTL4 gene
at p11.31
Genome profiles of 307 primary breast tumors and 47
cancer cell lines were established by aCGH. GISTIC
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by losses in more than 20% of tumor samples (Addi-
tional file 2, Figure S1). None of these losses were
homozygous deletions. Profiles showed various sizes of
losses (Figure 1A). In tumor T8700 loss within 18p11.31
(Figure 1A) spanned the L3MBTL4 gene only (Figure
1B). 18p losses including this region were found in 77
(25%) primary tumors and 19 (40%) cell lines.
Copy number transitions are likely to reflect DNA
strand breakages that may lead to nonreciprocal translo-
cations [26]. L3MBTL4 was targeted by copy number
transition in tumor T50115, and in the HCC38 (Figure
1C, D) and MDA-MB-453 cell lines. In T50115, the
breakpoint was within the genome interval [ch18:
6,202,799-6,212,615], which contains L3MBTL4 exons 10
and 11. The resulting protein should be truncated of its
C-terminal part starting from the second MBT motif. In
HCC38 and MDA-MB-453 the breakpoints spanned
genome intervals chr18: 6,009,803-6,020,061, (between
exons 17 and 18) and chr18: 6,030,519-6,044,093 (includ-
ing exon 16], respectively. These two breakages should
generate a protein truncated of the sterile alpha motif
(SAM) domain. None of these potential fusion transcripts
involving the L3MBTL4 gene has been identified yet.
Thus, the L3MBTL4 gene is targeted by various geno-
mic alterations, including loss and breakage, in a high
proportion of breast cancers.
Features of tumors with L3MBTL4 loss
L3MBTL1, L3MBTL2 and L3MBTL3 paralogs were not
targeted by deletion in our breast tumor set. We did not
find any L3MBTL4 deletion among genome profiles
similarly established in 80 colon cancers, 115 myeloid
hematopoietic diseases and 53 sarcomas (data not
shown). This suggests that L3MBTL4 loss occurs specifi-
cally in breast cancers.
Figure 1 Examples of chromosome 18 aCGH profiles. (A) Tumor T13708 on the left does not present any gene copy number aberration.
Tumors T6165, T8581, T11305, T8295, T9193, T6744 and T8700 exhibit copy number losses on the short arm of chromosome 18. The genomic
profile observed in tumor T8700 shows the smallest region targeted by the 18p loss. (B) The smallest deletion observed in breast primary tumor
T8700 targets the L3MBTL4 gene (18p11.31) and includes the minimal 18p common lost region, Chr18:6,366,938-6,375,929 bp defined with 96%
of studied tumors (Additional file 1, Table S4A). (C, D) Breakpoint targeting the L3MBTL4 gene in breast primary tumor T50115 and HCC38 breast
cancer cell line.
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out L3MBTL4 loss showed that L3MBTL4 loss was
often found together with the loss of four 17q genes:
ACCN1 (p = 2.5.10
-5), RHOT1 (p = 8.3.10
-5), PSMD11
(p = 1.3.10
-4), and MYO1 D (p = 1.8.10
-4) (Additional
file 1, Table S3).
The 77 tumors with L3MBTL4 loss comprised 18
luminal A, 27 luminal B, 17 basal, 9 ERBB2, 2 normal-
like (Table 1) and 4 non-informed tumors (Additional
file 1, Table S4A). Among these, 42 (55%) showed loss
of a regional part of chromosome 18p including the
L3MBTL4 gene. They included 8 luminal A, 15 luminal
B, 10 basal, 5 ERBB2, 1 normal-like and 3 non-informed
tumors. The minimal commonly deleted region (CDR)
including L3MBTL4 was defined for each molecular
subtype as chr18:6,366,938-6,798,785 bp in luminal A
(telomeric and centromeric limits were defined by
tumors T11348 and T8683, respectively and noted
[T11348-T8683]), chr18:3,784,366-6,202,799 bp in lumi-
nal B ([T9377-T50115]), chr18:6,285,396-6,375,929 bp in
basal ([T5142cc-T8700]), chr18:3,732,722-6,168,500 bp
in ERBB2 ([T9296]), chr18:5,520,302-8,628,361 bp in
normal-like ([T12652]) and chr18:5,200,158-11,854,021
bp in non-informed tumors ([T6744-T12662]) (Addi-
tional file 1, Table S4A).
The 35 other cases showed a loss of L3MBTL4 as a
consequence of the complete loss of the chromosome
18p. They included 10 luminal A, 12 luminal B, 7 basal,
4 ERBB2, 1 normal-like and 1 non-informed tumors.
Interestingly, the complete loss of the chromosome 18p
was associated with the luminal B molecular subtype (p
< 0.05), as well as cancer in older women (>50 years
old) (Additional file 1, Table S4B).
Taken together, a minimal 18p CDR, chr18:6,366,938-
6,375,929 bp within the L3MBTL4 locus, was defined in
74 tumors (Additional file 1, Table S4A). In T9296,
T50115 and T50136 the L3MBTL4 loss flanked this CDR
at the telomeric and centromeric borders, respectively.
Comparison of clinical features between breast tumors
with and without L3MBTL4 loss (Table 1) showed that
L3MBTL4 loss was associated with the presence of
lymph node metastases (p = 1.02 10
-2), high SBR grade
(p = 1.15 10
-2) and luminal B molecular subtype defined
by SSP classification [23] (p = 3.10
-5). No impact on sur-
vival was noted.
L3MBTL4 is targeted by mutations
We searched for mutation in L3MBTL4 exons in 180
and 47 of the aCGH-profiled tumors and cell lines,
respectively. Sequence analysis of the tumor samples
identified 32 variants including 25 synonymous (23 p.
I l e u 5 7 0 I l e u ,2p . V a l 2 0 1 V a l ) ,6m i s s e n s e( 3p . S e r 1 2 3 A s n ,
1 p.Ser493Leu, 1 p.Glu560Lys, 1 p.Ile615Ser) and 1 non-
sense (p.Tyr339X). In BT-483 cell line a missense
(p.Arg96Gln) mutation was identified. Figure 2A shows
two examples of mutation. The localization and nature
of the mutations are shown in Figure 2B. The p.Ser123-
Asn substitution and the nonsense mutation were
located in regions encoding the conserved MBT1 and
MBT3 motifs, respectively. The nonsense mutation
should generate a truncated L3MBTL4 protein without
C2HC zinc finger and SAM domains. The p.Arg96Gln
substitution in BT-483 should affect the MBT1 domain.
The SAM motif was also targeted by the p.Glu560Lys
substitution. We were able to show that the p.Ser123-
Asn and p.Tyr339X mutations found respectively in
T8584, T8847 and T9193 and in T8525, were acquired
( F i g u r e2 A ) .W ec o u l dn o tc o n f i r mt h a tt h eo t h e rm i s -
sense mutations are similarly somatic. However, they
w e r en o ti n c l u d e da sS N Po rm i s s e n s e si nN C B Id b
SNP build 131 [27].
Counting only the 7 potentially deleterious mutations
the frequency of such event would be 3.9% in tumor
samples.
Two mutated (missense mutation) tumors (T9193 and
T10003) were also deleted.
L3MBTL4 mRNA is downregulated in breast tumors
L3MBTL4 gene expression was measured using qRT-
PCR in normal breast tissues and 52 breast tumor sam-
ples including 16 with a loss of the L3MBTL4 gene
region (T7420, T8009, T8189, T8600, T8700, T9059,
T9398, T9888, T9941, T11348, T11485, T11568,
T10684, T12854, T13469, T13018), one mutated and
deleted (T10003), and one mutated but not deleted
(T8525). L3MBTL4 gene expression was quantified by
comparison with the expression of the housekeeping
GUS gene. Overall, tumor samples expressed a low level
of L3MBTL4 mRNA as compared with normal breast
tissue. L3MBTL4 mRNA level was decreased at least
two-fold in all tumors with L3MBTL4 loss as well as in
the mutated and non-deleted sample (Figure 3). Some
non-deleted tumors also exhibited low L3MBTL4
mRNA level suggesting that L3MBTL4 downregulation
could be attributed to several mechanisms including
deletions but also regulation of transcription.
We also determined L3MBTL4 gene expression in 229
tumor samples and 4 NB samples by using Affymetrix
microarrays. L3MBTL4 mRNA was downregulated (ratio
T/NB <0.5) in 166 tumors (72%). Comparative analysis
of these 229 samples identified a significant correlation
(p = 5.05 10
-4)b e t w e e nL3MBTL4 mRNA downregula-
tion and gene loss (Figure 4A). Downregulation of
L3MBTL4 mRNA was associated with luminal A, lumi-
nal B and ERBB2 molecular subtypes (p = 6.734 10
-43).
Deletion, mutation and expression data are described
in the Additional file 1, Table S4A and summarized in
Table 2.
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Page 5 of 13Table 1 Comparison of clinical features between breast tumors associated or not with L3MBTL4 loss (determined by
aCGH)
Characteristics (N) L3MBTL4 non deleted L3MBTL4 deleted p odds ratio
N = 230 N = 77
Age (300) 52 (22-84) 51 (24-82) 0.69
Histological type (255) 0.57
Ductal 152 (78%) 48 (79%)
Lobular 15 (8%) 5 (8%)
Medularry 12 (6%) 2 (3%)
Mixt 8 (4%) 3 (5%)
Other 7(4%) 3 (5%)
Clinical form (301) 0.11 1.76
IBC 33 (15%) 18 (23%) (0.87-3.5)
Non IBC 191 (85%) 59 (77%)
Pathological tumor size (240) 0.052
pT1 45 (25%) 8 (14%)
pT2 95 (52%) 28 (48%)
pT3 42 (23%) 22 (38%)
Pathological axillary lymph node status (266) 1.02E-02 0.46
Negative 96 (48%) 20 (30%) (0.24-0.85)
Positive 103 (52%) 47 (70%)
SBR grade (267) 1.15E-02
1 38 (19%) 3 (5%)
2 63 (31%) 25 (38%)
3 100 (50%) 38 (58%)
ER (275) 0.11 0.6
Negative 84 (40%) 19 (29%) (0.31-1.13)
Positive 125 (60%) 47 (71%)
PR (264) 0.32 0.74
Negative 96 (48%) 26 (41%) (0.4-1.36)
Positive 104 (52%) 38 (59%)
P53 (192) 0.39 1.38
Negative 87 (59%) 30 (67%) (0.65-3)
Positive 60 (41%) 15 (33%)
Ki67 (217) 0.23 0.64
Negative 53 (32%) 12 (23%) (0.28-1.36)
Positive 112 (68%) 40 (77%)
ERBB2 (226) 1 1.03
Negative 145 (85%) 48 (86%) (0.42-2.83)
Positive 25 (15%) 8 (14%)
Molecular subtype (264) 8.04E-04
Basal 63 (33%) 17 (23%)
ERBB2 22 (12%) 9 (12%)
Luminal A 52 (27%) 18 (25%)
Luminal B 29 (15%) 27 (37%)
Normal-like 25 (13%) 2 (3%)
Metastatic relapse (198) 0.32 0.62
no 135 (88%) 37 (82%) (0.23-1.78)
yes 18 (12%) 8 (18%)
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(TTMA, PTPN2, NDC80, SLMO1 and TUBB6) coordi-
nately deregulated with L3MBTL4 and also localized in
an 18p region frequently lost in breast tumors, suggest-
ing a common mechanism of deregulation of their
expression, which might contribute to breast
oncogenesis.
Correlations between L3MBTL4 microarray data and
clinical features of 229 tumors are reported in the Addi-
tional file 1, Table S5. The lowest expression of
L3MBTL4 was found in lobular tumors (p = 7,11.10
-12)
and in inflammatory breast cancers (p = 0.04) and was
associated with the expression of estrogen receptor (ER)
(p = 2,73.10
-14), progesterone receptor (PR) (p =
3,11.10
-13), ERBB2 (p = 7,73.10
-14), SBR grade 2 (p =
1.49 10
4), lymph node metastasis (p = 3,39.10
-5), P53
negativity (p = 0.0495) and low expression of Ki67 pro-
liferative index (p = 19,61 10
-5).
Sixty-four genes are targeted by 18p copy number losses
in breast cancer
To identify other 18p genes targeted by copy number
losses, a GISTIC analysis was done on the genome pro-
files of the 307 cases. Recurrent copy number losses tar-
geted 64 genes within the 18p11.21-11.32 region (p < 1
×1 0
-5) (Additional file 2, Figure S1), including
L3MBTL4 and the potential TSG EPB41L3/DAL1 [28].
This suggests that this 18p11 region probably hosts
multiple TSGs.
Fourteen new 18p TSG candidates
To identify these other potential 18p11 TSGs we com-
pared the degree of CNA-driven RNA downregulation
in the 307 samples by analyzing the genes common to
the genome and expression platforms (aCGH Agilent
Technologies and Affymetrix) and retained after filtering
based on the expression level. Sixty-three of the 64 were
c o m m o n .T h eg e n ee x p r e s s i o no f1 4g e n e s( YES1,
SMCHD1, LPIN2, MRCL3, MRCL2, ZFP161, RALBP1,
PPP4R1, NAPG, AFG3L2, SPIRE1, CEP76, PTPN2 and
SEH1L) was downregulated in relation with their copy
number losses (p < 0.05) (Additional file 1, Table S6).
We noted that EPB41L3/DAL1 and L3MBTL4 were not
retained. The lowest expression of EPB41L3 in breast
tumors was associated with the presence of lymph node
metastases (p < 0.05), correlated with basal and luminal
B molecular subtypes (p < 0.01) and showed clinical
impact (Additional file 1, Table S7).
Among the 14 genes, the downregulated expressions
of ZFP161, PPP4R1 and YES1 in breast tumors were
correlated with the luminal B molecular subtype
(p < 0.01). Interestingly, the downregulated expression
of ZFP161 was correlated with a poor clinical outcome
(5-years MFS, p = 1.7.10
-3; 5-years OS, p = 1.6.10
-3)
(Additional file 1, Table S8).
Discussion
L3MBTL4 gene alterations
Few works have reported the presence of TSGs on 18p
for breast cancer [1,2] and only EPB41L3/DAL1 [28] has
been identified as potential TSG involved in this neo-
plasm thus far. Our aCGH results provide a detailed
view of the alterations of chromosome arm 18p in
breast tumors. Losses at 18p11.31 occurred in 25% of
tumors and the smallest common region of deletion tar-
geted the L3MBTL4 l o c u sa n dw a sa l s ot h es i t eo f
breakages. The karyotype of the MDA-MB-453 cell line
displays a der(18)t(7;18) [29]. The L3MBTL4 breakpoint
suggests involvement of this gene in this alteration.
L3MBTL4 loss was associated with high grade and with
lymph node metastasis. In agreement, an increased risk
of relapse in patients with high risk breast cancer has
been associated with 18p loss [30]. L3MBTL4 loss was
associated with the luminal B subtype, which is charac-
terized by a poor prognosis. Interestingly, L3MBTL4 is
centromeric and in close proximity to the loss of hetero-
zygosity (LOH) region spanning EPB41L3 previously
reported in non-small cell lung carcinomas [1], breast
carcinomas [3], and meningiomas [31].
L3MBTL4 was targeted by point mutations in few cases.
These mutations clustered in the vicinity of the MBT or
SAM motifs. A study of L3MBTL1 has shown that a point
mutation in the second MBT repeat motif affected the
binding to H1K26me and H4K20me [32]. We surmise
that the nonsense mutation in the third MBT motif of
L3MBTL4 may have similar functional implication.
In three tumors and in the BT-483 cell line L3MBTL4
mutations were associated with the loss of the other
Table 1 Comparison of clinical features between breast tumors associated or not with L3MBTL4 loss (determined by
aCGH) (Continued)
Death from breast cancer (239) 0.38 0.73
no 139 (77%) 41 (71%) (0.36-1.52)
yes 42 (23%) 17 (29%)
5 year-Metastasis-free survival (198) 90% 81% 0.254
5 year-Overall specific survival (239) 78% 73% 0.271
Note: IBC, Inflammatory Breast Cancer; SBR, Scarf-Bloom-Richardson, histological grade.
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Page 7 of 13allele, suggesting a double-hit mechanism leading to
complete loss-of-function of L3MBTL4 in these samples.
We did not find homozygous mutations or deletions of
L3MBTL4. However, we cannot exclude that in addition
to these alterations, total inactivation could result from
promoter hypermethylation of the other allele. The
study of mRNA expression tended to confirm this.
L3MBTL4 loss of expression
Expression of L3MBTL4 level was decreased at least
two-fold in 73% of breast cancer samples, particularly in
tumors deleted at the L3MBTL4 locus since decreased
expression correlated with genomic alteration. All the
deleted tumors showed absence or decreased L3MBTL4
expression. Few cases displayed mRNA downregulation
in the absence of loss suggesting that other mechanisms
such as epigenetic repression play a role in the downre-
gulation of L3MBTL4 in breast tumors.
L3MBTL4 downregulated expression was not found
only in luminal B tumors but also in luminal A, luminal
B, ERBB2 and normal-like cases. Only the basal subtype
presented a normal expression of the gene, indepen-
dently of loss. This suggests that L3MBTL4 does not
play a TSG role in this subtype of breast cancer. Inacti-
vation of other TSGs may explain 18p losses in basal
breast cancers.
L3MBTL4 as a tumor suppressor gene
Our observations are in agreement with a previous study
that suggested the presence of TSGs on 18p with a role
in the genesis of breast cancer [33]. There are several
reasons to believe that L3MBTL4 is a good candidate
TSG. First, it lies within the region of chromosome 18
that is frequently deleted in breast cancers; L3MBTL4 is
also targeted by mutations and breakages and is dowre-
gulated in tumors. Second, L3MBTL4 gene is a human
homolog of Drosophila l(3)mbt,w h i c hf u n c t i o n sa sa
TSG in fly. The loss-of-function generated by mutation
of l(3)mbt causes brain tumors in Drosophila [4,5].
Third, L3MBTL4 has three paralogs that are suspected
Figure 2 Mutations of L3MBTL4 gene in 180 breast tumors and 47 breast cancer cell lines. (A) Examples of mutations in the L3MBTL4
gene. Sequence detects a c.368G>A mutation in exon 7 in T8584. Mutation c.1017C>G in exon 13 generates a stop codon in T8525. The
absences of the corresponding mutation in paired normal tissues (N8584 and N8525) suggest that the mutations were acquired. Vertical arrows
indicate the position of the mutation. (B) Representation of L3MBTL4 protein and localization of the mutations. For each tumor, mutations were
identified by sequence analysis and translated on the L3MBTL4 protein (lozenges). Primers and conditions used are described in the Additional
file 1, Table S2.
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Page 8 of 13to play a role in the etiology of certain types of cancer
[7]. L3MBTL1, a known transcriptional repressor [34],
has been proposed as a TSG gene in myeloid malignan-
cies associated with 20q deletion [8,35,36]. A recent
study reported focal hemi- and homozygous deletions of
L3MBTL2 and L3MBTL3 in medulloblastoma [9].
The four human L3MBTL proteins have MBT
domains involved in transcriptional repression and chro-
matin remodeling. The MBT domain was originally
identified in the Drosophila l(3)mbt protein [5] and
binds methyl-lysine residues [37,38], particularly and
strongly H3K9me and H4K20me [39]. The transcrip-
tional repressor L3MBTL1 requires its three MBT
domains for compacting chromatin and silencing [32].
Although the exact biochemical properties and cellular
functions of L3MBTL4 are unclear to date, the presence
of MBT domains in L3MBTL4 suggests that it interacts
with chromatin [40], may potentially bind methylated
histone and thus play a role in transcriptional regulation
of stem cell genes, oncogenes and tumor suppressors.
Loss of this regulator may thus affect several breast can-
cer genes. Some of these genes may be part of the E2F/
RB pathway. Indeed, the E2F/RB pathway is altered in
luminal B cancers and L3MBTL proteins are known to
regulate this pathway [7].
Taken together, our results suggest that aberrations
targeting L3MBTL4 could confer to cancer cells specific
advantages but do not exclude the role of other poten-
tial 18p candidates.
Other 18p TSG candidates
One of the potential 18p TSGs might be EPB41L3/
DAL1 [28], which is just telomeric to L3MBTL4,
between the D18S59 and D18S452 markers. However,
its expression was not correlated with that of L3MBTL4.
We also identified 14 TSG candidates whose gene
expression was downregulated in relation with their
copy number losses. We noted that EPB41L3/DAL1 and
L3MBTL4 w e r en o ti n c l u d e di nt h e1 4s u g g e s t i n gt h a t
their downregulated gene expression is not only the
consequence of their copy number loss but could result
from other mechanisms of deregulation including epige-
netic modifications. This is in agreement with study
showing that the hypermethylation of EPB41L3/DAL1
was associated with its downregulation in lung cancer
[41]. Our EPB41L3/DAL1 expression data showed that
Figure 3 Comparison of L3MBTL4 mRNA levels in deleted and non deleted breast tumors. mRNA levels were measured by quantitative
RT-PCR. GUSB mRNA expression was used as internal control for mRNA normalization. L3MBTL4 mRNA expression in deleted tumors was lower
than in normal breast (NB). Among the non-deleted tumors, L3MBTL4 mRNA expression was lower in luminal than in normal breast (NB) and
basal tumors. This suggests that the L3MBTL4 gene expression can be affected by heterozygous deletion but also regulated by an epigenetic
mechanism. Asterisk (*) indicates the mutated samples.
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Page 9 of 13its downregulation could be associated with an increased
risk of relapse in patients with high risk breast cancer.
EPB41L3/DAL1 undergoes allelic losses in various
cancers and in a significant proportion of ductal carci-
nomas in situ of the breast. The EPB41L3/DAL1 protein
suppresses the growth of MCF7 breast cancer cells and
increases attachment of these cells to a variety of
extracellular matrices [28]. Modulation of post-transla-
tional methylation may be an important mechanism
through which EPB41L3/DAL1 affects tumor cell
growth [42]. EPB41L3/DAL1 plays a critical role in the
suppression of lung tumor formation and metastasis
[43]. However, the role of EPB41L3/DAL1 as a TSG has
yet to be validated in vivo. EPB41L3/DAL1 deficient
Figure 4 Boxplots representing L3MBTL4 mRNA expression level in breast tumors. (A) Comparison of L3MBTL4 expression according to its
genomic status. L3MBTL4 expression level (log2 ratio) was lower in tumors with than without deletion (p = 5.05
e-4). Red and green horizontal
lines indicate thresholds (i.e. Basal tumors exhibited a normal mRNA expression (Figure 4B). However, the correlation between L3MBTL4 mRNA
downregulation and gene loss was not simply a consequence of the proportion of basal tumors in the category “tumors without loss”. Indeed, a
similar proportion of basal tumors [26% (15/58) and 32% (52/162)] was observed in both “tumors with loss” and “tumors without loss” groups,
respectively (Fisher test, p = 0.41). Moreover, downregulated L3MBTL4 expression was correlated with L3MBTL4 gene loss in basal tumors (p <
0.05).
Table 2 Summary of L3MBTL4 alterations
Samples Loss Mutation Loss
and mutation
Breakages *mRNA downregulation
Total tumors (N = 307; *229) 77 7(/180 studied) 2 1 166
Luminal A (N = 70; *66) 18 1 0 62
Luminal B (N = 56; *47) 27 1 0 1(T50115) 45
ERBB2 (N = 31; *23) 9 2 1 22
Basal (N = 80; *67) 17 1 1 16
Normal-like (N = 27; *26) 2 0 0 21
Not informed (N = 43) 4 2 0 0
Total cell lines (N = 47) 19 1 1 2 Not applicable
Luminal cell lines(N = 17) 12 1 1 (BT-483) 1 (MDA-MB-453) Not applicable
Basal cell lines (N = 9) 2 0 0 1 (HCC38) Not applicable
Others/Not done (N = 21) 5 0 0 0 Not applicable
* Samples analyzed by using DNA microarrays.
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Page 10 of 13mice are healthy and do not develop spontaneous
tumors [44]. Mutational screening failed to identify inac-
tivating mutation of the EPB41L3/DAL1 gene [33].
Among the 14 other TSG candidates, except PTPN2/
TCTP none has been so far associated with cancer.
PTPN2/TCPTP codes for the T-cell protein tyrosine
phosphatase (TCPTP) and is an important negative reg-
ulator of SFK, JAK1 and STAT3 signaling during the
cell cycle [45]. TCPTP suppresses the tumorigenicity of
glioblastoma cells expressing a mutant epidermal growth
factor receptor [46]. CEP76 encodes a centrosomal pro-
tein controling centrosome duplication during cell divi-
sion. Abnormal centrosome duplication contributes to
mitotic failure, genome instability, aneuploidy, and can-
cer. Depletion of CEP76 drives the accumulation of cen-
trosome intermediates in certain types of cancer cells
[47]. Only the downregulated expressions of ZFP161,
PPP4R1 and YES1 were correlated with the luminal B
subtype suggesting their potential involvement in the
genesis of a particularly aggressive form of breast cancer
with 18p loss. The downregulated expression of ZFP161
in breast tumors was correlated with a poor clinical evo-
lution. ZFP161/ZF5 encodes a ubiquitously-expressed
protein originally identified by its ability to bind and
repress the murine Myc promoter [48,49]. The protein
contains an N-terminal POZ domain, which recruits
cofactors to modulate transcription [50]. ZFP161/ZF5
mediates both transcriptional activation and repression
of cellular and viral promoters [48,50,51]. ZFP161 may
compete with MYC-induced transcription [52].
PPP4R1 encodes the regulatory subunit of a ~125-kDa
protein phosphatase. PPP4R1 interacts with PPP4C
[53,54] which is implicated in the regulation of histone
acetylation, DNA damage checkpoint signaling, NFB
activation, and microtubule organization at centrosomes
[55-59]. YES1 encodes a SRC-family kinase [60] and its
tyrosine kinase activity has been shown to be elevated in
colonic adenomas compared to its activity in adjacent
normal mucosa [61]. A number of studies have linked
increased expression of YES in cancer with increased cell
motility and tumor invasion [62,63]. It is then surprising
to find YES1 among the 18p TSG candidates. The down-
regulation of YES1 could be the consequence of its loss
as a simple passenger of a larger region lost within 18p.
Conclusion
We have delineated a region of frequent loss in breast
cancer on chromosome arm 18p. We have identified
L3MBTL4 as the gene targeted by these losses.
L3MBTL4 is also targeted by mutations and breakages.
L3MBTL4 mRNA expression is low in non-basal breast
tumors and in particular in tumors with loss of the
gene. Alteration of L3MBTL4, coding for a regulator of
epigenetic marks, is well in line with recent advances in
cancer research [64,65]. We have also pointed to other
18p TSG candidates including ZFP161, CEP76, PPP4R1
and PTPN2 whose involvement might explain the
aggressive phenotype of breast tumors with 18p loss.
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Additional file 1: Supplementary Tables S1-S8. Table S1. Clinical and
histological features of 307 breast tumor cases. Table S2. Primers used for
L3MBTL4 sequence determination. Table S3. Association of genes with
copy number alterations and L3MBTL4 genomic loss. Table S4A. The 77
tumors with L3MBTL4 loss and mutation. Table S4B. Correlations between
clinical features of 305 BC and the loss of whole chromosome 18p. Table
S5. Correlations between clinical features of 229 BC and L3MBTL4 gene
expression. Table S6 - Other potential 18p TSG candidates. Table S7.
Correlations between clinical features of 260 BC and EPB41L3 gene
expression. Table S8. Correlations between clinical features of 260 BC and
down regulated ZFP161 gene expression.
Additional file 2: Supplementary figure. Figure S1. The 18p is
targeted by losses in breast cancer. On the top, combining the CNA
frequency and gene copy number alterations level, the GISTIC algorithm
plotted the score index observed in genomic profiles of 307 breast
tumors as a function of chromosome 18 locations. The chromosome arm
18p was targeted by losses in more than 20% of tumor samples. The
dotted line indicates the threshold of significance for the score. At the
bottom, the figure shows only an 18p11.21-p11.32 region of 12.79 Mb
including 64 loci as significant 18p losses (p < 10
-5). L3MBTL4 and
EPB41L3 are contained within this region.
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